Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polyadenylate-binding protein cytoplasmic 3 (PABPC3) is an RNA-binding protein that specifically binds the poly(A) tail of mRNA and is thought to play a role in the cytoplasmic regulation of mRNA metabolism, including the stabilization of mRNA and initiation of translation[6][3][5]. PABPC3 is primarily expressed in testes, especially within spermatocytes and round spermatids, and is implicated in the control of mRNA translation during spermatogenesis[2]. Its expression levels are correlated with male infertility, particularly non-obstructive azoospermia, where decreased PABPC3 expression associates with more severe germ cell loss[2]. PABPC3 binds poly(A) sequences with lower affinity than its paralog PABPC1 and is not presently considered a classic therapeutic target, receptor, enzyme, transporter, or transcription factor[3][6][5]. There are no known direct drug interactions, biomarker roles, or specific safety concerns related to targeting PABPC3 identified in current literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polyadenylate-binding protein cytoplasmic 3 (PABPC3).